National Comprehensive Cancer Network
NCCN Oncology Research Program (ORP)
NCCN ORP Scientific Publications
NCCN ORP Investigator Steering Committee
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Insights: Analytics, Research & Consulting
NCCN Virtual Reimbursement Resource Room
NCCN Health Information Technology Licensees
NCCN Research & Business Resources
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
Select a cancer below for additional information on active trials.
Adenoid Cystic Carcinoma
Alan L. Ho, MD, PhD
Memorial Sloan-Kettering Cancer Center
A Phase II Study of Axitinib (AG-013736) in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Gynecologic Cancer
Head and Neck Cancers
Jeffrey Allen, MD
University of Tennessee Cancer Institute
A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Matthew Fury, MD, PhD
Memorial Sloan-Kettering Cancer Center
A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Matthew Fury, MD, PhD
Memorial Sloan-Kettering Cancer Center
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane®) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients with Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Alan L. Ho, MD, PhD
Memorial Sloan-Kettering Cancer Center
A Multi-Institution Phase II Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Theodoros N. Teknos, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
A Phase I Trial of Vorinostat in the Treatment of Advanced Oropharyngeal Carcinoma of the Head and Neck” Award
Francis P. Worden, MD
University of Michigan Comprehensive Cancer Center
Phase II Trial Evaluating Axitinib in Patients with Unresetable, Recurrent or Metastatic Head and Neck Cancer
Hematologic Malignancies
Kidney Cancer
Lung Cancer
Melanoma
Nikhil I. Khushalani, MD
Roswell Park Cancer Institute
Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma
Neuroendocrine/Carcinoid Tumors
Pancreatic Adenocarcinoma
Prostate Cancer
Sarcomas
Solid Tumors
Thyroid Cancer
Clinicians
Patients/Caregivers
Insurers/Employers/Case Managers
Pharma/Biotech
Industry Analysts